Prometheus Biosciences, Inc. (RXDX)

NASDAQ: RXDX · IEX Real-Time Price · USD
47.10
-2.40 (-4.85%)
Aug 11, 2022 4:00 PM EDT - Market closed
-4.85%
Market Cap 1.85B
Revenue (ttm) 6.29M
Net Income (ttm) -108.32M
Shares Out 39.20M
EPS (ttm) -2.78
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 722,014
Open 49.17
Previous Close 49.50
Day's Range 45.51 - 49.44
52-Week Range 21.12 - 51.96
Beta n/a
Analysts Buy
Price Target 54.99 (+16.8%)
Earnings Date Aug 10, 2022

About RXDX

Prometheus Biosciences, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of novel therapeutics and companion diagnostics products for the treatment of inflammatory bowel diseases (IBD). Its lead product includes PRA023, a humanized IgG1 monoclonal antibody (mAb), which is in Phase IIa clinical trial for the treatment of ulcerative colitis and Crohn's disease, as well as systemic sclerosis-associated interstitial lung disease. The company also develops PR600, an anti-tumor necrosis factor mAb for IB... [Read more...]

Industry Biotechnology
IPO Date Mar 12, 2021
Employees 72
Stock Exchange NASDAQ
Ticker Symbol RXDX
Full Company Profile

Financial Performance

In 2021, RXDX's revenue was $3.13 million, an increase of 154.60% compared to the previous year's $1.23 million. Losses were -$90.20 million, 142.9% more than in 2020.

Financial Statements

Analyst Forecast

According to 16 analysts, the average rating for RXDX stock is "Buy." The 12-month stock price forecast is 54.99, which is an increase of 16.75% from the latest price.

Price Target
$54.99
(16.75% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Prometheus Biosciences, Inc. (RXDX) Reports Q2 Loss, Tops Revenue Estimates

Prometheus Biosciences, Inc. (RXDX) delivered earnings and revenue surprises of 6.52% and 81.29%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Prometheus Biosciences Reports Second Quarter 2022 Financial Results and Highlights Recent Corporate Progress

- Both topline ARTEMIS-UC Phase 2 and full APOLLO-CD Phase 2a results expected concurrently in 4Q 2022  -

Prometheus Biosciences to Host a Virtual R&D Day for Analysts and Investors on July 26, 2022

- The event will feature Prometheus management and key opinion leader presentations on PR600 target unveiling, scientific rationale, and corresponding therapeutic candidate, PRA052 -

Prometheus Biosciences Completes Enrollment of the ARTEMIS-UC Cohort 1 Phase 2 Study in Ulcerative Colitis

- G lobal Phase 2 placebo-controlled trial enrolled twice as fast as the industry average, establishing a roadmap for future studies -

Prometheus Biosciences Provides Enrollment Update in APOLLO-CD and ARTEMIS-UC Global Phase 2 Studies

- Enrollment completed ahead of schedule for APOLLO-CD Phase 2a study of PRA023 in Crohn's disease patients -

Prometheus Biosciences, Inc. (RXDX) Reports Q1 Loss, Tops Revenue Estimates

Prometheus Biosciences, Inc. (RXDX) delivered earnings and revenue surprises of -5.13% and 459.86%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the s...

Prometheus Biosciences Reports First Quarter 2022 Financial Results and Highlights Recent Corporate Progress

- Advanced and expanded development of PRA023 across three immune-mediated indications -

Prometheus Biosciences Initiates Third Phase 2 Study of PRA023 for Systemic Sclerosis-Associated Interstitial Lung Di...

- First therapeutic candidate for the treatment of SSc-ILD targeting both key fibrotic and inflammatory pathways -

Prometheus Biosciences Reports Fourth Quarter and Full-Year 2021 Financial Results and Highlights Recent Corporate Pr...

- Topline results for ongoing Phase 2 clinical trial in ulcerative colitis and Phase 2a trial in Crohn's disease expected in fourth quarter 2022 -

Prometheus Biosciences to Participate at the 11th Annual SVB Leerink Global Healthcare Conference

SAN DIEGO, Feb. 07, 2022 (GLOBE NEWSWIRE) -- Prometheus Biosciences, Inc. (Nasdaq: RXDX), a clinical-stage biotechnology company pioneering a precision medicine approach for the discovery, development, ...

Prometheus Biosciences to Present at the 40th Annual J.P. Morgan Virtual Healthcare Conference

SAN DIEGO, Jan. 05, 2022 (GLOBE NEWSWIRE) -- Prometheus Biosciences, Inc. (Nasdaq: RXDX), a clinical-stage biotechnology company pioneering a precision medicine approach for the discovery, development, ...

These were the 10 best performing IPOs of 2021 amid a record year for stock market debuts

Global IPOs have raised $453 billion in proceeds, representing a 67% increase year-over-year and a more than doubling from 2019 levels.

Prometheus Biosciences Posts Phase 1 Data On Lead Therapeutic Candidate

Prometheus Biosciences Inc (NASDAQ: RXDX) has reported topline results from its Phase 1 trial of PRA023 in healthy volunteers. PRA023 was well-tolerated, with no safety signal identified during the study.

Prometheus Biosciences Reports Positive Topline Phase 1 Data on Lead Therapeutic Candidate PRA023; Expands Indication...

Phase 1 trial achieved primary objective of safety and tolerability and demonstrated favorable outcomes on other key endpoints, including target engagement and immunogenicity

Prometheus Biosciences Reports Third Quarter 2021 Financial Results and Highlights Recent Corporate Progress

- Full clinical trial results from Phase 1a trial of PRA023 and announcement of a third Phase 2 indication for PRA023 expected in fourth quarter 2021 -

How to Use New Analyst Coverage to Find Strong Stocks to Buy

One way to find potential winning stocks is to search for companies that recently landed new analyst coverage.

Other symbols: LTRXUGI

Prometheus Biosciences to Present at Upcoming Investor Conferences

SAN DIEGO, Nov. 02, 2021 (GLOBE NEWSWIRE) -- Prometheus Biosciences, Inc. (Nasdaq: RXDX), a clinical-stage biotechnology company pioneering a precision medicine approach for the discovery, development, ...

Prometheus Biosciences to Present at Jefferies Virtual Next Generation IBD Therapeutics Summit

SAN DIEGO, Oct. 12, 2021 (GLOBE NEWSWIRE) -- Prometheus Biosciences, Inc. (Nasdaq: RXDX), today announced that Mark McKenna, Chairman and Chief Executive Officer and Allison Luo, M.D., Chief Medical Off...

Prometheus Biosciences Reports Second Quarter 2021 Financial Results and Highlights Recent Corporate Progress

- Initiated Phase 2 study of PRA023 and its companion diagnostic in Ulcerative Colitis (UC) and Phase 2a study of PRA023 and its companion diagnostic in Crohn's disease (CD) -

In Memoriam – Friend, Scientific Innovator, Advisor and Board Chair Dr. Tadataka Yamada Has Passed Away

SAN DIEGO, Aug. 05, 2021 (GLOBE NEWSWIRE) -- Prometheus Biosciences, Inc. (Nasdaq: RXDX), with great sorrow announced today that its Chairman of the Board, Tadataka (Tachi) Yamada, M.D., KBE, passed awa...

Prometheus Biosciences Achieves Milestone Payment from Dr. Falk Pharma GmbH Further Validating the Prometheus360™ Pla...

-Prometheus receives $10 million payment triggered by selection of clinical candidate for PR600-

Prometheus Biosciences to Present at 2021 Jefferies Virtual Healthcare Conference

SAN DIEGO, May 25, 2021 (GLOBE NEWSWIRE) -- Prometheus Biosciences, Inc. (Nasdaq: RXDX), a clinical-stage biotechnology company pioneering a precision medicine approach for the discovery, development, a...

3 Small Cap Stocks That Are Short Squeeze Candidates

Low float stocks can be some of the most volatile stocks in the market. If you mix in a short squeeze, the potential short-term gains in a low float stock can be extreme.

Other symbols: GTHWRLD

Prometheus Biosciences to Present at 2021 RBC Capital Markets Global Healthcare Conference

SAN DIEGO, May 14, 2021 (GLOBE NEWSWIRE) -- Prometheus Biosciences, Inc. (Nasdaq: RXDX), a clinical-stage biotechnology company pioneering a precision medicine approach for the discovery, development, a...